ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Neoplasm Metastasis

Breast Cancer trials near New Haven, CT, USA:

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.The inte...

Active, not recruiting
Breast Cancer
Drug: Carboplatin
Drug: Nivolumab

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 9 other locations

This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PAL...

Enrolling
Breast Cancer
Stage II Breast Cancer
Drug: Niraparib
Drug: Dostarlimab

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

New Haven, Connecticut, United States and 8 other locations

participants with early-stage high-risk hormone receptor positive breast cancer.The names of the study drugs involved in this study...

Enrolling
Breast Cancer
High Risk Breast Carcinoma
Drug: Exemestane
Drug: Abemaciclib

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 11 other locations

This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination ...

Active, not recruiting
Breast Cancer
Drug: Endocrine Therapy
Drug: Tamoxifen

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 10 other locations

This research study is for patients with metastatic breast cancer.* Metastatic means that the cancer has spread beyond the ...

Active, not recruiting
Somatic Mutation Breast Cancer (BRCA1)
Somatic Mutation Breast Cancer (BRCA2)
Drug: Olaparib

Phase 2

Beth Israel Lahey Health
Beth Israel Lahey Health

Commack, New York, United States and 19 other locations

This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast...

Active, not recruiting
Metastatic Breast Cancer
Breast Carcinoma
Drug: LEE-011
Drug: Fulvestrant

Phase 2

Melissa K Accordino

Stony Brook, New York, United States and 12 other locations

therapy as a treatment after surgery for hormone receptor positive breast cancer.The study drugs involved in this study are:* A com...

Enrolling
Breast Cancer
Hormone Receptor Positive Breast Cancer
Drug: ADJUVANT ENDOCRINE THERAPY
Combination Product: Pertuzumab+TRASTUZUMAB

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 27 other locations

Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies avail...

Enrolling
Breast Cancer
Breast Neoplasm
Drug: Cyclophosphamide
Drug: Interferon infiltration of the inoculation site

Phase 3

BriaCell Therapeutics

Port Jefferson Station, New York, United States and 12 other locations

of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast...

Enrolling
Breast Cancer
Drug: Adjuvant Therapy
Drug: Palbociclib

Phase 2

Criterium

New Haven, Connecticut, United States and 14 other locations

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...

Active, not recruiting
Metastatic Breast Cancer
Drug: Tucatinib
Drug: Durvalumab

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Commack, New York, United States and 71 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems